West to Host Fourth-Quarter and Full-Year 2021 Conference Call

EXTON, Pa., Feb. 3, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2021 financial results before the market opens on Thursday, February 17, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call, please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 1986145.

A live broadcast of the conference call will be available at the Company's website, www.westpharma.com, in the "Investors" section. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company's website. 

An online archive of the broadcast will be available at the site three hours after the live call and will be available through Thursday, February 24, 2022, by dialing 855-859-2056 (U.S.) or 404-537-3406  (International). The conference ID is 1986145.

About West

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With almost 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 40 billion components and devices each year.

Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2020 generated over $2.15 billion in sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit https://www.westpharma.com/.

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.

SOURCE West Pharmaceutical Services, Inc.